The use of complementary and alternative medicine by patients in routine care and the risk of interactions
Rachel Firkins(Jena University Hospital), Jutta Huebner(Jena University Hospital), Hannah Eisfeld(Jena University Hospital), Andreas Hochhaus(Jena University Hospital), Thorsten Schmidt(University of Tübingen), Christina Keinki(Jena University Hospital), Jens Buentzel(Südharz Klinikum)
Cited by 77
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis
|The Lancet Neurology|2004|1.1k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
|The Lancet Oncology|2012|505
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464